International Stem Cell Corporation Completes Dosing Of Second Cohort In Parkinson’s Disease Clinical Trial – Nasdaq
|
International Stem Cell Corporation Completes Dosing Of Second Cohort In Parkinson's Disease Clinical Trial
Nasdaq CARLSBAD, Calif., March 05, 2018 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that the eighth … |
